Blog Post » Roads Not Taken

Julius Axelrod was one of NIMH’s greatest scientists and mentors for five decades until his death in 2004 at age 92. In addition to his many discoveries - which led to his 1970 Nobel Prize - Julie, as he was known, was famous for his aphorisms. One was his saying that “98 percent of the discoveries are made by 2 percent of the scientists.” While this might sound arrogant or elitist to some, data emerging over the past few years support the notion that much of our scientific endeavor involves following the herd and, importantly, that the herd grazes on not much more than 2 percent of the available land.

In a paper published last year in Nature entitled “Too many roads not taken,” Aled Edwards and his colleagues provide a nice example of this instinct.1 The class of enzymes called kinases are critical biological gatekeepers, and many are potentially involved in diseases of the brain. Although there are over 500 protein kinases known from the human genome, about 65 percent of the 20,000 kinase papers published in 2009 focused on the same 50 that were being studied in the early 1990’s. This narrow focus has persisted after many of the unexplored kinases showed up in unbiased genomic screens as potentially related to diseases.

The narrow focus of our science is even more conspicuous in this age of “-omics” – when we can study all of the genes, all of the transcripts, or all of the proteins without a hypothesis. Although we thought the fields of genomics, transcriptomics, and proteomics had defined the universe of roads not taken, recent publications from the ENCODE project reveal a dramatic expansion of this universe.2 ENCODE is a landmark effort that is mapping the working parts of the human genome and exposing just how limited our exploration has been to date. Researchers have focused mostly on the 2 percent of the genome that belongs to genes, but we now know that 80 percent of the genome is translated. In fact, the genome codes for a range of important biological signaling molecules, many of which are still being identified.

For the past 50 years, NIMH researchers have focused on a few pages of this vast text, assuming that dopamine and serotonin were most of what we needed to know about the biology of mental disorders. Where we have been is akin to colonial North America where the overwhelming majority of the population remained on a small fraction of the continent and the Midwest and West were frontiers explored by very few.

How do we encourage exploration of the vast frontiers of biology? How do we nudge the scientific field toward the unknown? In truth, much of what we currently do reinforces herd behavior. NIMH funding is guided largely by a system of peer review, and peer review tends to reward the familiar or, at best, small steps. But the problem is much more fundamental than this. Scientific training is based on an apprenticeship model, with the focus placed on following a mentor, not on breaking for a frontier. Furthermore, academic success requires publishing, which is most easily accomplished by remaining where the tools are good, the field is safe, and the territory is familiar. Not all kinases, for example, are equally easy to study. Successful scientists know to focus on problems that have a good chance of being solved. As the British biologist Sir Peter Medawar noted, “Science is the art of the soluble.” But the targets that are easiest to study are not always the most important. We have created a world of incentives for looking where the light is, even if that is not where the keys were lost.

This would not matter so much if our problems were not so important to solve. We simply cannot afford to have 98 percent of our scientists looking where the light is, staying within the safe zone. Given this, NIH has been working to build incentives to help attract the most intrepid scientists into the frontiers of science. NIH’s Pioneer Awards and New Innovator Awards are grants for innovative ideas that are opening new areas to research and creating new tools. Importantly, these awards are for the person, not the specific project, encouraging these scientists to pursue novel approaches to important problems. For example, a recent NIMH-supported Pioneer Award will allow Feng Zhang of MIT to develop a new approach to manipulating the genome and epigenome.3

NIMH is also trying to encourage innovation among young investigators through the BRAINS (Biobehavioral Research Awards for Innovative New Scientists) initiative. So far, we have awarded 28 early stage investigators with support to pursue an idea deemed high-risk but high-reward, helping to move them into areas not previously studied. Among the 28, Amit Etkin4 of Stanford is studying the neurobiology of psychotherapy, and Zhaolan Zhou5 of the University of Pennsylvania is defining the epigenetic signature of early life stress.

My own sense is that Julie Axelrod was partly right. There is a small group of scientific leaders who seek out new frontiers and set the pace for the vast majority of the field. But I am not convinced that tells the entire story. Each new breakthrough is based on a foundation laid by hundreds of scientists often working in distant fields. Today we find that discoveries are often the products of groups working together, rather than a lone investigator striving to be in the 2 percent club. At the same time, we do need to make more room for scientific pioneers - researchers who have completely new ideas and are willing to take risks to open up a new area of inquiry.

This need is important to consider during this period of austerity for NIMH funding. Tight budgets are not kind to risk takers. But, when budgets are tight, it is more important than ever to shore up support for the innovators who are not following familiar paths. At NIMH we are using the Pioneer and New Innovator initiatives, our own BRAINS awards program, and a policy of supporting grants that are trying new approaches even when the peer review scores are beyond our nominal payline. If there is any lesson to be learned from the many discoveries of this past year, it is that the continent we need to explore is both larger and more complex than we ever imagined. With so many roads not yet taken, who would want to follow the herd?

 1 Edwards AM, Isserlin R, Bader GD, Frye SV, Willson TM, Yu FH. Too many roads not taken. Nature. 2011 Feb 10;470(7333):163-5. PMID: 21307913

 2 The September 6, 2012 issue of Nature includes multiple articles pertaining to the ENCODE project. Information about the project and related publications are accessible via Nature’s ENCODE web pages: http://www.nature.com/encode/External Link: Please review our disclaimer.

 3 Additional information about this project may be accessed at: http://projectreporter.nih.gov/project_description.cfm?projectnumber=1DP1MH100706-01

 4 Additional information about this project may be accessed at: http://projectreporter.nih.gov/project_info_description.cfm?aid=8319594&icde=14517184

 5 Additional information about this project may be accessed at: http://projectreporter.nih.gov/project_info_description.cfm?aid=8299100&icde=14517215

Science News » Switching Off a Specific Brain Region Can Alter Ingrained Habits in Rats

Ingrained habits in rats can be quickly broken—and reestablished—by targeting and switching off a specific site in the brain’s prefrontal cortex using a technique known as optogenetics, according to an NIMH-funded study published November 13, 2012, in the Proceedings of the National Academy of Sciences (PNAS).

Background

rat in a maze

Source: iStock Photo

Studies have established that the prefrontal region of the brain is associated with habit formation and expression. It is also linked to emotion regulation and to regions in the brain that are associated with behavioral flexibility, which counteracts habit.

Kyle Smith Ph.D., Ann Graybiel Ph.D., of the Massachusetts Institute of Technology, and colleagues, trained rats to run a T-shaped maze. At the decision point, the rats were cued to turn to either one side, where chocolate milk awaited them as a reward, or to the other side, where the reward was sugar water. Eventually, running the maze and responding to each cue correctly became a habit, and the rats continued to do so even after the rewards were removed.

The researchers then returned the rewards but paired the chocolate milk with exposure to lithium chloride, which causes nausea. Once the rats realized the milk made them ill, they declined to drink it. However, they continued to run the maze and turn toward the chocolate milk side of the maze when cued, indicating that running in that direction when prompted had become a nearly automatic behavior.

Results of the Study

To determine whether the habit could be broken, the researchers then applied a technique known as optogenetics—in which a laser light is delivered to brain cells through optical fibers—to see if they could manipulate a specific region of the rats’ prefrontal cortex known as the infralimbic (IL) cortex. When the laser was turned on and the IL cortex was disrupted, the rats nearly instantaneously stopped running habitually toward the chocolate milk reward. Instead, they appeared to act more thoughtfully, running toward the other side, where the untainted sugar water awaited.

Once the rats were broken of the habit of running automatically to the chocolate milk side, they began to develop a habit of always running to the other side, even when they were cued to run toward the chocolate milk, and even after the untainted chocolate milk was returned. But when the IL region was again disrupted optogenetically, the rats returned to their original habit of running to the chocolate milk side when cued to do so.

Significance

Control of a small part of the prefrontal cortex can change whether or not habits are expressed. An old habit can be blocked abruptly, and a new habit can override it. But if the new habit is then blocked, the old habit returns, thus lending credence to the notion that old habits die hard.

In addition, the fact that habitual behavior can be altered if IL activity is disturbed suggests that the circuitry in this region of the brain is coordinating on some level with other brain regions that directly access circuits involved in behavioral flexibility, as well as addictive behaviors.

What’s Next

Although the optogenetic technique is too invasive to use in humans, it does have implications for potentially disrupting destructive habits. Targeting this specific region of the brain could lead to better ways of controlling addiction disorders or mental disorders in which habitual behaviors are out of balance, such as obsessive compulsive disorder.

Reference

Smith K, Virkud A, Deisseroth K, Graybiel A. Reversible online control of habitual behavior by optogenetic perturbation of media prefrontal cortex. PNAS. Nov 13, 2012. 109(46):18932-18937.

Yaz Lawsuit Complaints Update

Yaz and Yasmin are two contraceptives made by the German pharmaceutical company, Bayer. These drugs have been linked to blood clots and other related conditions. Plaintiffs in the Yaz Lawsuit  claim that Bayer did not adequately portray the risks associated with their products.

Yaz and Yasmin are both considered fourth generation contraceptives and therefore contain the synthetic hormone, drospirenone. Drospirenone has been linked to a rise in potassium levels in woman’s bodies. The elevated potassium can cause heart rhythm disturbances which in turn can lead to blood clotting. If left untreated, blood clots can cause a plethora of other complications or even death.

These effects do not have a specified time frame, as women have reported experiencing blood clots or related events in any range of times after the initial use of Yaz or Yasmin.

Because of these risks many medical journals are suggesting that women do not use Yaz, Yasmin, or any other 4th generation contraceptive for that matter. Instead it is suggested that a 2nd or 1st generation be used instead, as these have been shown to be the safest.

Yaz and later Yasmin implored an aggressive marketing campaign that portrayed these drugs as relatively safe. The plaintiffs claim that Bayer did not accurately portray the risks associated with Yaz or Yasmin, in their advertisements. These women seek settlement for the unintended pain that they suffered.

Currently, Bayer has settled almost 3500 of the Yaz and Yasmin cases, already this has cost Bayer $750 million and the final number will likely be in the billions. The Yaz and Yasmin lawsuits currently lead the country in most pending litigation with over 8,000 cases yet to be settled. The time for the plaintiffs to actually receive compensation will be long and arduous.

 

Technorati Tags:

Bayer Continues to Settle Yaz Lawsuits

11/15/2012  German pharmaceutical company, Bayer, has settled over 3000 of the cases in the Yaz Lawsuit cases. These settlements have cost the company no less than $750 million, and with over 8,000 cases left to settle, this number can only go up. An estimated $1.5 billion will have been paid to the plaintiffs by the end of proceedings. As of right now, the Yaz suit has the most cases in pending litigation in the entire United States.

Yaz Lawsuit

Originally introduced in 2001 as an oral contraceptive medication, Yaz and similar products contain a synthetic form of progestin called drospirenone. Drospirenone has been shown to elevate levels of potassium in women’s blood. Elevated potassium levels can cause a slowing of heart pumping actions. This can eventually lead to serious blood clots forming in patient’s bodies. These clots can move elsewhere in the body causing even more complications.

After an excessive marketing campaign, Yaz managed to become the most popular contraceptive in the United States. This is due in part to Yaz’s heavily publicized ability to decrease other problems associated with the menstrual cycle.

Due to the excessive amount of women who used Yaz, an excessive amount saw the related side effect of various blood clots and in some cases galbladder problems or death because of the drospirenone. This proves to be a problem for Bayer, as they did not release this information prior to FDA approval.

The plaintiffs in the Yaz lawsuit claim that Bayer should have known of the potentially lethal side effects of their medication. Others claim that Bayer in fact did know of the increased risk but pursued FDA approval nonetheless. In either case, the plaintiffs have very solid points.

Technorati Tags:

Granuflo Dialysis Lawsuit Continues to Develop

11/14/2012 Granuflo Dialysis Lawsuit News:  The world’s largest manufacturer of dialysis treatments is currently battling a vicious lawsuit that is threatening its credibility. Fresenius Medical Care Inc. is in danger due to the once-popular drug, GranuFlo.

GRANUFLO LAWSUIT

GranuFlo is an additive used to improve dialysis treatments, and help out people suffering from ailments such as kidney failure. Complications for Fresenius arose when an inordinate amount of GranuFlo patients began suffering from heart attacks. Individuals and families of those who were effected are filing Granuflo Lawsuit cases.

This was especially controversial considering that Fresenius had not released any information regarding Granuflo heart attacks.

Plaintiffs in the Granuflo dialysis lawsuit claim that Fresenius intentionally hid the information about these very dangerous side effects from the public.

Dialysis Lawsuit

These claims were backed when the FDA uncovered a memorandum that had allegedly circulated within Fresenius. This memo, which was circulated around Fresenius, showed that the company had specific knowledge of Granuflo-related heart attacks at least four months before the FDA.

This memo was allegedly given to Fresenius-owned dialysis clinics, but the information was not presented to anyone outside of the company.

In response to the high death rate associated with GranuFlo users and the alleged actions of Fresenius, the FDA has put a Class 1 recall on GranuFlo. Class 1 is the most serious recall that the FDA can issue.

In light of everything, Fresenius has very little legal actions that they can take to rid themselves of these serious claims.

The world’s largest manufacturer of dialysis treatments is currently battling a vicious lawsuit that is threatening its credibility. Fresenius Medical Care Inc. is in danger due to the once-popular drug, GranuFlo.

GranuFlo is an additive used to improve dialysis treatments, and help out people suffering from ailments such as kidney failure. Complications for Fresenius arose when an inordinate amount of GranuFlo patients began suffering from heart attacks.

This was especially controversial considering that Fresenius had not released any information regarding Granuflo heart attacks.

Plaintiffs in the Granuflo dialysis lawsuit claim that Fresenius intentionally hid the information about these very dangerous side effects from the public.

These claims were backed when the FDA uncovered a memorandum that had allegedly circulated within Fresenius. This memo, which was circulated around Fresenius, showed that the company had specific knowledge of Granuflo-related heart attacks at least four months before the FDA.

This memo was allegedly given to Fresenius-owned dialysis clinics, but the information was not presented to anyone outside of the company.

In response to the high death rate associated with GranuFlo users and the alleged actions of Fresenius, the FDA has put a Class 1 recall on GranuFlo. Class 1 is the most serious recall that the FDA can issue.

In light of everything, Fresenius has very little legal actions that they can take to rid themselves of these serious claims.

Dialysis Lawsuit

Dialysis Lawsuit

Technorati Tags:

Yaz and Yasmin and Ocella Lawsuit News

111/14/2012  Yaz, Yasmin and Ocella Lawsuit News.   Best Legal Source encourages women who have been injured by the birth control pill Yaz to call our helpline (800) 611-7080 to arrange a free Yaz Lawsuit consultation with a Yaz Lawsuit attorney who is knowledgeable in pharmaceutical litigation.  Per a U.S. Food and Drug Administration warning letter, side effects associated with the use of Yaz include venous and arterial thrombotic and thromboembolic events, such as myocardial infarction and thromboembolism (a blood vessel blocked by a small piece that has broken away from a blood clot at its site of formation).  Utilize our service today to locate an experienced Yaz Lawsuit attorney for your potential Yaz Lawsuit.

Yaz Lawsuit

Combination birth control pills, such as Yaz, are oral contraceptives that combine a synthetic estrogen and different types of progestins.  Unlike other combination birth control pills, Yaz contains the progestin, drospirenone, which may increase your potassium levels possibly causing serious heart issues and other problems.  There have also been concerns raised about drospirenone containing combination birth control pills increasing the risk of developing blood clots, including deep vein thrombosis, pulmonary embolism and heart attack.  Yaz Lawsuit groups want to convey that the U.S. Food and Drug Administration (FDA) is evaluating all available information so they can assess the risks of drospirenone containing birth control and venous thromboembolism.  The FDA will continue to communicate any new safety issues as it becomes available.  A Yaz Lawsuit is for those who took Yaz and developed serious injury due to the blood clots they developed.

Ocella Lawsuit

It has been alleged that the manufacturer of Yaz, who also makes Yasmin and Ocella,  marketed these  products without disclosing certain facts regarding serious and potentially fatal side effects.  You may be entitled to financial compensation through a Yaz Lawsuit if you have suffered from any Yaz side effects.  Yaz Lawsuit attorneys are the most qualified individuals when you need to know your legal rights.  If your physical health was harmed by Yaz, do not hesitate to call Best Legal Source at (800) 611-7080 or complete the form on the right of this page.  We will make the legal process toward a Yaz Lawsuit settlement easier for you.

Technorati Tags: , ,

The Dialysis Lawsuit case continues to unfold

Granuflo Dialysis Lawsuit

Granuflo Dialysis Lawsuit

11/16/2012 As the Dialysis Lawsuit against Fresenius Medical Care continues to unfold,  more evidence is coming to light that does not bode well for the defendant. The fact that Granuflo and Naturalyte have been Linked to heart attacks has already lead to Granuflo Lawsuit cases as well as Naturalute Lawsuits being investigated by Plaintiffs Lawyers.  The discovery process in the Dialysis Lawsuit cases is likely to  uncover more evidence against Fresenius than has already been made public by the company and the FDA.

It is already known that Fresenius delayed notifying clinics of the problems with Granuflo and Naturalyte when it was discovered that an alarming number of heart attacks were occurring among dialysis patients that were receiving Granuflo and Naturalyte as part of their dialysis treatments. It has also already been established that when the FDA instructed Fresenius to notify dialysis clinics that used Granuflo and Naturalyte of the link to heart attacks, the company only notified clinics that it owned at first. The delay in notifying dialysis clinics not owned by Fresenius could very well have cost the lives of some dialysis patients.  It is incomprehensible to many observing this case as to why Fresenius delayed the process of letting dialysis clinics know about the issues with their products.

In cases like the Dialysis Lawsuit, as it has come to be called,  the actions of the defendant after the fact often become as central to the litigation as the facts that the litigation stemmed from in the first place. When pharmaceutical companies and medical device manufacturers place loss mitigation strategies before human life, they often pay the consequences in higher jury awards and even fines and lawsuits from Government agencies. Having seen this scenario play out many times , it is astounding that pharmaceutical companies and medical device manufacturers have not learned that it is better to get in front of a situation where there products are harming people, than it is to worry first about loss mitigation strategy.

If you or a loved one suffered a heart attack during the time you were receiving dialysis treatments, please contact us to arrange a free legal consultation about your potential dialysis lawsuit.

 

Technorati Tags: , ,

New Complications in the Vaginal Mesh Lawsuit

Vaginal Mesh Lawsuit News Update

Vaginal Mesh Lawsuit News Update

11/14/2012 Manufacturers of Vaginal Mesh Products may face new Vaginal Mesh Lawsuit cases from States. Although over two thousand Vaginal Mesh Lawsuits have already been filed by women who suffered injuries as a result of vaginal mesh products, cases bu Government entities add a new twist to the situation. If you were injured by a Vaginal Mesh Product and have yet to  consult with legal counsel, please follow this link  to arrange a free consultation with a Vaginal Mesh Lawyer : File a Vaginal Mesh Lawsuit.

Vaginal Mesh Lawsuits filed by States

It is not unusual for States and even the Federal Government to bring their own lawsuits in pharmaceutical and Medical device cases. The facts that lead to individuals filing cases like Vaginal Mesh Lawsuits often , in part or in whole , are based on issues that involve regulatory violations or violations of law. When a Medical Device manufacturer or a Pharmaceutical Company violates State and or Federal Regulations, these Government entities can bring lawsuits and criminal charges against the manufacturer. The cost of settling the cases brought by Government agencies can often exceed the cost of settling the lawsuits brought by the individuals who were injured by the products.

Ramifications of Vaginal Mesh Lawsuit cases filed by Government Entities

In some cases, a Government entity might bring its case against a manufacturer after lawsuits by individuals are settled. In other cases the Government’s action may precede any lawsuits brought by individuals. In the Vaginal Mesh Lawsuit, it appears that at least some Government entities may bring cases against some manufacturers of Vaginal Mesh Products during while the Vaginal Mesh Lawsuits by individuals are ongoing. The discoveries made in any government investigations could impact the Vaginal Mesh Lawsuits filed by individuals in a positive manner.

The Vaginal Mesh Lawsuit has a lengthy future

The Vaginal Mesh Lawsuit is likely to be going for some time. The possible involvement of Government Entities filing there on cases could serve to lengthen the life span of the case. In addition, the fact that not all women who have been injured have filed a vaginal mesh lawsuit contributes to the likelihood of a lengthy future for the case. Lastly, many women currently have vaginal  mesh implants that have yet to become problematic but may at any time. The pool of potential Vaginal Mesh Lawsuit plaintiffs filing future cases is not quantifiable at this point in time.

For more information relevant to the Vaginal Mesh Lawsuit, refer to the website of the FDA.

Technorati Tags:

Pradaxa Bleeding Antidote, Too Little Too Late for Pradaxa Lawsuit Plaintiffs

11/16/2012 Pradaxa Lawsuit Plaintiffs will not be helped by an Antidote created after they were injured.   The announcement that the maker of Pradaxa was

Pradaxa Lawsuit and Vitamin K

Pradaxa Lawsuit and Vitamin K

working on an Antidote for bleeding events caused by Pradaxa is too little too late for Pradaxa Lawsuit plaintiffs who have filed wrongful death cases as a result of a Pradaxa Related Bleeding event that cost the life of their loved one.

To those in the legal community that  are filing Pradaxa Lawsuit cases on behalf of Pradaxa Bleeding victims, the fact that the maker of Pradaxa is reportedly now working on an Antidote to stop Pradaxa Bleeding episodes is in essence an admittance that such an antidote should have been developed before releasing Pradaxa to the public.   Given that it is known that the traditional antidote for bleeding events caused by drugs similar to Pradaxa does not work for bleeds caused by Pradaxa, its seems logical that the maker of Pradaxa would have developed an antidote for Pradaxa related bleeds before a large number of people lost their lives due to Pradaxa Bleeding events that could not be controlled.

Although we have had no reports that the maker of Pradaxa denies that they knew the traditional antidote that works for similar drugs would not work with Pradaxa any such denial would be questionable. Given that one of the benefits of Pradaxa allegedly promoted by the manufacturer was the fact that individuals who used Pradaxa could eat foods that contained Vitamin K.  Given that Vitamin K is the antidote for bleeding events caused by drugs similar to Pradaxa,  people who took those drugs had to restrict their diet to avoid Vitamin K.   These drugs act as blood thinners, to ingest foods with Vitamin K in them would have counteracted the effects of the drug. Vitamin K was only used when a bleeding event occurred. The dietary restrictions for individuals taking drugs similar to Pradaxa were significant as many vegetables contain vitamin K.

Given that the maker of Pradaxa touted the fact that taking Pradaxa did not require the dietary restrictions that came with similar drugs, it would be difficult for the maker of Pradaxa to now claim that they were unaware that Vitamin K would not work as an Antidote for Pradaxa Related Bleeding Events .

If you or a family member suffered a bleeding event while taking Pradaxa that required medical attention, please call our toll free number to arrange a free legal consultation about your potential Pradaxa Lawsuit.

Technorati Tags:

The Yaz Lawsuit and Nuvaring Lawsuit, similar cases take different paths

Yaz Lawsuit and Nuvaring Lawsuit

Yaz Lawsuit and Nuvaring Lawsuit

11/16/2012 Although the Yaz Lawsuit and the Nuvaring Lawsuit have much in common, the defendants in the respective cases have taken a very different approach.

Bayer, the maker of Yaz is currently settling Yaz Lawsuit claims at a fast pace as they previously announced they intended to do. Bayer seems to be taking the approach that the best thing to do for those injured by Bayer as well as the company itself is to make compensation to those who were injured and put the matter to rest.

While Bayer seems to have the desire to put the Yaz Lawsuit matter behind them, the maker of Nuvaring has taken a different approach.  Numerous delays have occurred in the Nuvaring Multidistrict Litigation. Many Plaintiffs Lawyers content that the maker of Nuvaring has been dilatory  with their efforts to delay Nuvaring Lawsuit trial dates for as long as possible.  The delays will some come to an end however, as the presiding judge in the Nuvaring  Multidistrict Litigation has now set trial dates for the first Nuvaring cases to be heard. The first Nuvaring trials are set to being in the first half of 2013.

Nuvaring Lawsuit Plaintiffs as well as their Lawyers are now speculating that the maker of Nuvaring may change its strategy now that court dates have been set. Nuvaring Lawsuit plaintiffs are hoping that the maker of Nuvaring  will adopt an approach more similar to the approach Bayer is now taking with Yaz Lawsuit cases. Nuvaring Lawsuit plaintiffs have waited , in some cases for several years, while medical bills mounted and other damages they allege were caused by Nuvaring have not been addressed in any tangible way.

If you took Yaz or used Nuvaring, there is still time to inquire about filing a Yaz Lawsuit or a Nuvaring Lawsuit. Contact our toll free number to arrange a free legal consultation.

Technorati Tags: ,